Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKSFL0)

Drug Name

SB-242235 Drug Info

Synonyms

193746-75-7; SB-242235; SB242235; SB 242235; 4-(4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)-2-methoxypyrimidine; CHEMBL95692; 4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]-2-methoxypyrimidine; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]-2-methoxypyrimidine; Kinome_3169; SCHEMBL2267209; BDBM15458; SYN1076; PDTYLGXVBIWRIM-UHFFFAOYSA-N; MolPort-028-720-427; HMS3244I18; HMS3244J17; HMS3244I17; EX-A1881; BCP05992; ZINC1487129; 3254AH; RS0056; AKOS027323444; CS-2097; NCGC00345831-01; NCGC00345831-03

Indication

Disease Entry	ICD 11	Status	REF
Arthritis	FA20	Discontinued in Phase 1	[1]

Cross-matching ID

PubChem CID: 9863367
TTD Drug ID: DMKSFL0

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Stress-activated protein kinase 2a (p38 alpha)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ozagrel	DMIGKA1	Xerophthalmia	5B55.Y	Phase 4	[3]
Losmapimod	DMIL37Z	Acute coronary syndrome	BA41	Phase 3	[3]
VX-702	DMKJDR6	Coronary artery disease	BA80	Phase 2a	[4]
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[5]
Dilmapimod	DMBYJ92	Acute lung injury	NB32.3	Phase 2	[3]
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[6]
PMID25991433-Compound-F2	DM37VIQ	N. A.	N. A.	Patented	[6]
PMID25991433-Compound-L2	DM58UO9	N. A.	N. A.	Patented	[6]
PMID25991433-Compound-L3	DM3LWUR	N. A.	N. A.	Patented	[6]
PMID25991433-Compound-L1	DM2135Y	N. A.	N. A.	Patented	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HSPB1 messenger RNA (HSPB1 mRNA)	TT9AZWY	HSPB1_HUMAN	Inhibitor	[2]
Stress-activated protein kinase 2a (p38 alpha)	TTQBR95	MK14_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010787)
2	Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4433-7.
3	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
4	Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
5	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
6	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.